Last updated: February 19, 2026
This report analyzes the market dynamics and financial trajectory of CI 45410, a pharmaceutical excipient. The excipient's current market penetration, patent landscape, and projected growth are detailed, with a focus on key drivers and potential investment opportunities.
What is CI 45410 and Its Role in Pharmaceutical Formulations?
CI 45410, also known as D&C Red No. 30, is a synthetic organic compound. Its primary function within pharmaceutical formulations is as a colorant. It provides a specific red hue, enhancing the visual appeal and aiding in product identification of oral solid dosage forms, such as tablets and capsules, and some topical preparations.
- Chemical Structure: CI 45410 is a laked form of D&C Red No. 28, characterized by its barium salt structure.
- Regulatory Status: Approved for use in drugs and cosmetics by the U.S. Food and Drug Administration (FDA) under specific limitations and guidelines.
- Functionality: Beyond coloration, its inert nature ensures it does not interfere with the active pharmaceutical ingredient's (API) efficacy or stability. Its particle size and dispersibility are critical for uniform distribution within a formulation.
What is the Current Market Size and Projected Growth for CI 45410?
The market for CI 45410 is a sub-segment of the broader pharmaceutical excipients market. Precise, standalone market size data for CI 45410 is not extensively disaggregated in public reports, as it is often grouped with other colorants. However, the global pharmaceutical excipients market was valued at approximately $9.3 billion in 2022 and is projected to reach $16.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1% (Source: Grand View Research). CI 45410's growth is influenced by these overarching trends.
- Growth Drivers:
- Increasing demand for oral solid dosage forms, particularly generics, which rely on colorants for identification.
- Expansion of pharmaceutical manufacturing in emerging economies.
- Growing consumer preference for visually appealing and easily distinguishable medications.
- Market Challenges:
- Increasing regulatory scrutiny on colorants, leading to potential restrictions or the need for reformulation.
- Competition from alternative colorants, including natural dyes and other synthetic options, offering different color profiles or perceived safety advantages.
- Supply chain volatility for raw materials.
Based on the growth of the broader excipient market and the specific applications of CI 45410, its market is estimated to grow at a CAGR of 4-6% over the next five years. This estimate considers its established use in numerous legacy products and its continued adoption in new formulations where its specific hue is desired.
Who Are the Key Manufacturers and Suppliers of CI 45410?
The production of CI 45410 is concentrated among a limited number of specialized chemical manufacturers. These companies typically possess the expertise and regulatory compliance necessary for producing pharmaceutical-grade excipients.
- Major Suppliers:
- Sensient Technologies Corporation: A prominent global manufacturer of colors, flavors, and fragrances, including pharmaceutical-grade colorants.
- D.F. Anstead Ltd.: Known for its specialized color solutions for pharmaceutical and cosmetic applications.
- ROSE GMBH: Manufactures pharmaceutical excipients, including colorants, for the global market.
These manufacturers operate under strict Good Manufacturing Practices (GMP) and quality control protocols to ensure the purity, consistency, and safety of CI 45410 for pharmaceutical use. The competitive landscape is characterized by product quality, regulatory support, and the ability to meet diverse customer specifications.
What is the Patent Landscape Surrounding CI 45410?
CI 45410 itself, as a well-established chemical entity, is in the public domain and not subject to direct patent protection for its basic chemical structure. However, patents related to CI 45410 primarily concern its novel applications, improved manufacturing processes, and specific formulations incorporating it.
- Areas of Patent Activity:
- Formulation Innovations: Patents may cover specific tablet or capsule formulations that utilize CI 45410 for enhanced drug delivery, stability, or taste masking, where the colorant plays a synergistic role.
- Manufacturing Process Improvements: While the core synthesis is known, patents might exist for more efficient, cost-effective, or environmentally friendly methods of producing high-purity CI 45410.
- Combination Excipients: Patents could protect formulations where CI 45410 is used in conjunction with other excipients to achieve specific physical or chemical properties for a drug product.
Example Patent Trends: A review of patent databases (e.g., USPTO, EPO, WIPO) reveals a moderate but steady stream of patent applications filed in the last decade related to novel pharmaceutical compositions. These patents often claim specific combinations of APIs and excipients, including colorants like CI 45410, for improved therapeutic outcomes or manufacturing ease. The number of such patents remains lower than for novel APIs, reflecting its role as an auxiliary material.
What are the Regulatory Considerations for CI 45410 Use?
Regulatory compliance is paramount for any pharmaceutical excipient. CI 45410 is subject to stringent regulations by health authorities worldwide.
- FDA Regulations (United States):
- CI 45410 is listed in the Code of Federal Regulations (CFR) Title 21, Part 73, Appendix B.
- It is permitted for use in drugs and cosmetics as a color additive.
- Restrictions may apply to the maximum concentration allowed in finished drug products and specific dosage forms.
- Manufacturers must adhere to FDA's current Good Manufacturing Practices (cGMP).
- European Medicines Agency (EMA) Regulations (Europe):
- Excipients must comply with the European Pharmacopoeia (Ph. Eur.) monographs.
- The use of colorants is governed by Regulation (EC) No 1333/2008 on food additives, which also impacts pharmaceuticals due to overlapping safety standards.
- Other Global Regulations: Health Canada, Japan's Ministry of Health, Labour and Welfare (MHLW), and other national regulatory bodies have their own specific requirements for excipient approval and use.
Key Compliance Aspects:
- Purity Standards: Excipients must meet defined purity profiles, with strict limits on heavy metals and other potential contaminants.
- Traceability: Manufacturers must maintain robust traceability systems for raw materials and finished excipient batches.
- Documentation: Comprehensive documentation, including Certificates of Analysis (CoA) and Drug Master Files (DMF), is required to support regulatory submissions by pharmaceutical companies.
What is the Financial Performance and Investment Outlook for CI 45410 Producers?
The financial performance of companies producing CI 45410 is intrinsically linked to the broader pharmaceutical excipients market and the specific demand for colorants. While direct financial data for CI 45410 production is not separately reported by public companies, key indicators from the excipient sector provide insight.
- Revenue Streams: Revenue is generated through the sale of high-purity CI 45410 to pharmaceutical manufacturers. Pricing is influenced by production volume, purity grades, and customer contracts.
- Profitability: Profit margins for excipient manufacturers are generally stable, driven by the recurring demand from the pharmaceutical industry. However, significant R&D investment is not typically required for established excipients like CI 45410, leading to moderate profit margins compared to API development.
- Investment Considerations:
- Stable Demand: The consistent need for colorants in generic and branded pharmaceuticals provides a stable revenue base.
- Regulatory Barriers to Entry: The high cost and complexity of meeting pharmaceutical excipient regulations create a barrier to new entrants, benefiting established players.
- Consolidation Trends: The pharmaceutical excipient market has seen consolidation, with larger players acquiring smaller specialists to expand their product portfolios and geographic reach. This trend may continue.
- Innovation Risk: While CI 45410 itself is not an area for high-risk innovation, companies that can offer integrated solutions, such as novel blends of colorants or specialized particle sizes, may gain a competitive advantage.
Companies with strong regulatory compliance, established supply chains, and efficient manufacturing processes are best positioned for sustained financial performance. Investment in this segment is characterized by a focus on operational excellence and market share defense rather than disruptive technological breakthroughs.
Key Takeaways
- CI 45410 is a synthetic red colorant crucial for pharmaceutical product identification and appeal, particularly in oral solid dosage forms.
- Its market growth is tied to the expanding global pharmaceutical excipients market, estimated at $9.3 billion in 2022, with projected CAGR of 4-6% for CI 45410.
- Key manufacturers include Sensient Technologies, D.F. Anstead Ltd., and ROSE GMBH, operating under strict GMP standards.
- Patent activity for CI 45410 focuses on novel formulations and process improvements, not the core chemical entity.
- Strict regulatory compliance with FDA, EMA, and other global bodies is essential, requiring high purity and comprehensive documentation.
- Financial performance for producers is stable, driven by consistent demand, with investment potential centered on operational efficiency and market share within the consolidated excipient industry.
Frequently Asked Questions
1. Can CI 45410 be used in liquid pharmaceutical formulations?
CI 45410 is primarily approved and used for coloring solid oral dosage forms and some topical preparations. Its application in liquid formulations is less common and may be subject to different regulatory considerations and formulation challenges related to solubility and stability in liquid matrices.
2. What are the primary alternatives to CI 45410?
Primary alternatives include other D&C Red dyes (e.g., D&C Red No. 7, D&C Red No. 28), FD&C Red No. 40, and a range of natural colorants like carmine, beet red, and anthocyanins, depending on the desired hue, regulatory approval, and formulation compatibility.
3. How does the cost of CI 45410 compare to other pharmaceutical colorants?
The cost of CI 45410 is competitive within the synthetic organic colorant category. Its price is influenced by manufacturing complexity, purity requirements, and market volume. Synthetic dyes generally offer greater consistency and cost-effectiveness than many natural alternatives.
4. What are the typical batch sizes produced for CI 45410 by manufacturers?
Batch sizes for pharmaceutical-grade excipients like CI 45410 can vary significantly based on the manufacturer's production capabilities and customer demand. They can range from hundreds of kilograms to several metric tons per batch to meet the needs of large-scale pharmaceutical production.
5. Are there any known safety concerns or adverse effects associated with CI 45410 in pharmaceuticals?
When used within approved concentration limits and according to regulatory guidelines, CI 45410 is considered safe for pharmaceutical applications by regulatory bodies like the FDA. As with all color additives, comprehensive toxicological data supports its safety profile for intended uses.
Citations
[1] Grand View Research. (2023). Pharmaceutical Excipients Market Size, Share & Trends Analysis Report By Type (Binders, Fillers, Disintegrants, Lubricants, Colorants, Others), By Application (Oral, Parenteral, Topical, Ophthalmic), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/pharmaceutical-excipients-market
[2] U.S. Food and Drug Administration. (n.d.). Color Additive Status List. Retrieved from https://www.fda.gov/cosmetics/color-additives-cosmetics/color-additive-status-list
[3] European Medicines Agency. (n.d.). Guidance on excipients. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice/guidance-excipients
[4] Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. Official Journal of the European Union, L 354/16.
